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Active and passive immunization to angiotensin in experimental
acute renal failure. A number of studies support, and others fail
to support, the concept that the renin-angiotensin system plays a
key role in the pathogenesis of acute renal failure. This study,
employing active and passive immunization against angiotensin
11, was designed to examine the primacy of circulating angio-
tensin as a mediator of this syndrome. Neither mode of im-
munization significantly affected the degree of azotemia or the
marked reduction of inulin clearance expected in rats subjected to
glycerol-induced myohemoglobinuria. Twenty-four hours after
challenge, inulin clearance (CIN) in actively immunized rats fell
to 3.2% of control and that of unimmunized rats given the same
dose of glycerol was 2.5% of control. Although there was some
variation among groups of passively immunized rats, CIN of one
group being l8% of control, CIN of the other groups was less
than 3% of control. The dose and binding capacity of the im-
mune globulin used here were essentially the same as those re-
ported in another study in which immunization was thought to
be of prophylactic value in rats subjected to s.c. administered
glycerol injections. Technologic differences unrelated to im-
munization are suggested to have caused the difference in results
in the two studies, and it seems doubtful that circulating angio-
tensin plays a key role in the pathogenesis of myohemoglobinuric
acute renal failure in the rat.
Immunisation active et passive contre l'angiotensine dans
l'insuflisance rénale expérimentale. Des résultats contradictoires
ont été obtenus en ce qui concerne le role primordial du système
rénine angiotensine dans Ia pathogénie de l'insuffisance rénale.
Ce travail, qui utilise l'immunisation active et passive contre
l'angiotensine II, a été concu de facon a évaluer la primauté de
l'angiotensine circulante comme médiateur du syndrome d'in-
suffisance rénale. Aucun des deux procédés d'immunisation ne
modifie significativement l'importance de l'azotémie et la diminu-
tion nette de la clearance de l'inuline qui sont escomptées chez
des rats soumis a une myoglobinurie induite par le glycerol,
Vingt quatre heures après le déclenchement, CIN de rats im-
munisés activement décroit a 3,2% des valeurs contrOles alors
que chez les rats non immunisés uric valeur égale a 2,5% des
contrOles est obtenue. Bien qu'il y alt une certaine hétérogénéité
dans les groupes de rats immunisés passivement, CIN d'un
groupe est en effet a l8% des contrOles, l'ensemble des valeurs
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des autres groupes est inférieur a 3°/ des contrOles. La dose et Ia
capacité de liaison de Ia globuline immune utilisée dans ce
travail sont les mémes que celles publiées dans une autre étude
dans laquelle une valeur prophylactique avait été accordée a
l'imrnunisation de rats soumis a des injections sous cutanées de
glycerol. 11 est suggéré que des differences méthodologiques peu-
vent être a l'origine des discordances des deux travaux et il parait
douteux que l'angiotensine circulante puisse jouer un rOle
majeur dans Ia pathogénie de l'insuffisance rénale aiguë myoglo-
binurique du rat.
The renin-angiotensin system was first suggested to
play a role in the pathogenesis of acute renal failure
more than 30 yr ago [1]. Plasma renin and angiotensin
concentrations are markedly increased in patients with
this syndrome [2—5] and in rats during the early phases
of experimental acute renal failure [6—8]. The finding
that long-term saline loading protects rats from
various forms of acute renal failure [9—11] has been
attributed to concomitant renin depletion. On the
other hand, biologically effective immunization against
renin has been found not to protect rats from either
mercury-induced or myohemoglobinuric renal failure
[7], and angiotensin inhibitors do not appear to in-
fluence the development of experimental acute renal
failure [12]. Recently, however, Powell-Jackson et a!
have reported that passive transfer of rabbit anti-
angiotensin antibody confers protection against
glycerol-induced myohemoglobinuric renal failure in
the rat [13]. In addition, Rauh et al have stated in a
recent abstract that they, too, were able to prevent
glycerol-induced renal failure in rats with rabbit anti-
angiotensin antibody, but gave no details of their re-
sults [8]. Such a phenomenon, if substantiated, would
provide firm evidence linking the pathogenesis of
filtration failure to the renin-angiotensin system.
This joint study has been undertaken to reexamine
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the effect of active and passive immunization against
angiotensin on the development of myohemoglobin-
uric acute renal failure in the rat.
Methods
Active immunization against angiotensin II. Female
Sprague-Dawley rats (COBBS, Charles River Breeding
Laboratories, North Wilmington, MA) were im-
munized against synthetic angiotensin complex using
a modification of the method of Goodfriend, Levine
and Gasman [14], as reported previously [15]. Ten mg
of synthetic asparaginyi-5-valine angiotensin II (CIBA,
Summit, NJ) and 5 mg of rat albumin (Pentex,
Kankakee, IL) were dissolved in 0.25 ml of distilled
water and mixed with 75 mg of 1-cyclohexyl-3-(2 mor-
pholino-ethyl) carbodiimide (Aldrich Chemical Co.,
Milwaukee, WI) dissolved in 0.12 ml of distilled water.
"Mock" antigen was prepared similarly but without
angiotensin. The mixture was stirred for one hour at
room temperature and dialyzed against 1 liter of dis-
tilled water at 5°C for two periods totalling 24 hr. The
antigen and mock antigen complexes were added to
equal volumes of complete Freund's adjuvant. Well-
mixed emulsion, 0.03 ml, freshly prepared, was in-
jected into the footpads of female Sprague-Dawley rats
weighing 95 to 110 g four times at ten-day intervals.
After the immunization series was completed, ran-
domly chosen animals were anesthetized with 40 mg/
kg of body wt of sodium pentobarbital i.p. and given
2 mg of pentolinium tartrate subcutaneously (s.c.). A
femoral vein tributary was cannulated with polyethy-
lene tubing for subsequent injection of norepinephrine
and angiotensin. A carotid artery was cannulated for
measurement of arterial blood pressure by direct mer-
cury manometry. All animals received 250 United
States Pharmacopoeia Units (USPU) of heparin
sodium (Liquaemin). Norepinephrine and angiotensin,
10 g/ml, were injected using separate calibrated
microsyringes (Cole Palmer, Chicago, IL) at a dose of
5 x l0 g, each solution into a different femoral vein
tributary. These agents were injected alternately, the
blood pressure response to each being determined two
or three times in every animal. Repeat injections were
given three to five minutes after a stable baseline blood
pressure had been re-attained.
In vitro neutralization of angiotensin was assayed by
incubating l0- g of angiotensin for one hour at 37°C
with 2-mi samples of plasma anticoagulated with dis-
odium EDTA, 10 moles/ml. to inhibit angiotensinase
activity. Aliquots (0.1 ml each) of the incubation
mixtures (containing 5 x l0 g of angiotensin) were
injected into assay rats prepared as already described,
and the blood pressure response compared with that
seen after injection of 5 x l0 g of angiotensin or
norepinephrine in saline.
Acute renal failure was produced in actively im-
munized rats by injecting 10 ml/kg of body wt 50%
glycerol i.m. in divided doses into the hind limbs [17].
The rats were allowed free access to water prior to
challenge.
Preparation and assay of antibody for passive im-
munization. Rabbit antiagiotensin II antibody was
prepared according to the method of Goodfriend et al
[14], as described previously [13], in the Medical Re-
search Council Blood Pressure Unit of the Western
Infirmary, Glasgow. Immunizing antigen was pre-
pared as already described except that bovine serum
albumin was substituted for rat albumin. Antibody
PS1O was a pooled serum preparation obtained from
two New Zealand white rabbits; preparation W3 was a
pooled sample obtained by repeatedly bleeding a third
rabbit. Gammaglobulin was isolated in the cold by
ammonium sulfate fractionation (45% wt/voi), di-
alyzed against 0.9% NaC1 and lyophilized. According
to measurement, each 1 ml of serum PS1O yielded
29 mg of lyophilized antibody-salt mixture used in
these experiments.
Passive immunization. The ability of isolated rabbit
antiangiotensin gammaglobulin to modify the blood
pressure response to angiotensin injection was assessed
in normal adult female rats. The antibody was dis-
solved in saline, 50 mg/ml, and redialyzed against
1 liter of 140 m saline at 5°C for 24 hr. Rats, 210 to
232 g in weight, were anesthetized with sodium pento-
barbital, 40 mg/kg of body wt, and prepared for arte-
rial manometry and i.v. injections as already described.
Synthetic angiotensin II and norepinephrine were in-
jected alternately at doses of 10_B to 3 x 10_8 g i.v.
beginning ten minutes after i.v. injection of 10 mg of
P510 or 20 mg of W3 antibody.
Normal female Sprague-Dawley rats with a mean
body wt of 226±5 (sEM) g were deprived of drinking
water for 14 hr prior to study. A 0.2-mi blood sample
was taken from the tail for measurement of baseline
blood urea nitrogen (BUN) concentration and hemato-
crit value. The rats were lightly anesthetized with ether
and were given 55 mg or 75 mg of PS1O rabbit anti-
angiotensin gammaglobulin dissolved in 0.3 ml of nor-
mal saline i.v. Ninety mg of antibody preparation W3,
a less potent antibody, was injected in identical fashion
into a second group of animals. Fifty % glycerol in
water was then injected i.m. into each hind limb at a
total dose of 10 mi/kg of body wt. The animals were
lightly re-anesthetized with ether one hour after, and
again two hours after, glycerol injection, at which times
one-half of the original amount of antibody in 0.15 ml
of 140 mrvi NaC1 was injected i.v. The total volume
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administered in the three injections was 0.6 ml.
Twenty-four hr after glycerol injection, the animals
were anesthetized with 50 mg/kg of sodium pento-
barbital for measurement of renal function. BUN
concentration was measured with an autoanalyzer
(Technicon).
Measurement of glomerular filtration rate. 4C-inulin
(New England Nuclear Corporation, Cambridge, MA)
was injected at a dose of 10 Ci i.v. followed by a con-
tinuous infusion of 0.02 iCi/min in saline. The bladder
was catheterized per urethram using a 2-cm length of
PE9O tubing. A 20-mm equilibration period was
allowed after which the bladder was completely
emptied, and 0.1-ml blood samples were obtained
from the tail for measurement of '4C activity. Further
blood samples were taken 30 mm later and again at the
end of the one-hour clearance period. Two-1.d aliquots
of plasma and urine were assayed for '4C-inulin
activity using a liquid scintillation counter (Nuclear
Chicago) and a scintillating solution containing 700 ml
of toluene, 300 ml of ethanol, 3 g of Cab-O-Sil and 5 g
of butyl-PBD/liter.
Statistical analyses were performed according to the
method of Snedecor [6]. Values given represent the
mean I SEM.
Results
Biological effectiveness of active immunization. In-
travenous injections of 5 x 10 angiotensin or fore-
pinephrine in 11 angiotensin-immunized and 5 mock-
immunized rats produced the blood pressure response
shown in Table 1. Starting at comparable basal blood
pressures after pentolinium injection, angiotensin-
immunized rats had a markedly blunted response to
angiotensin (P <0.001); their response to norepine-
phrine was comparable to that shown by their mock-
immunized counterparts.
Two-ml plasma samples of five angiotensin-immu-
nized rats anticoagulated with disodium EDTA, 10
moles/mi, were incubated with 10 g of angiotensin
for 60 mm at 37°C and injected i.v. At a nominal an-
giotensin dose of 5 x 10 g, 0.1 ml of the mixture
caused the blood pressure of pentolinium-treated
assay rats to rise by 2± 1 (SE) mm Hg. Plasma of five
mock-immunized rats, anticoagulated, mixed with the
same amount of angiotensin and injected similarly,
produced a blood pressure rise of 13.9±2.7 (sEM)
mm Hg. The latter value is not different from 13.4
3.5 mm Hg obtained with injections of 5 x l0 g of
angiotensin in saline.
Activity ofpassively transferred antibody. Before glob-
ulin isolation, a 1/64,000 dilution of PS1O antiserum
bound 50% of lO g of '251-Asp'-11e5-angiotensin 11
Table 1. Blood pressure response of actively immunized and
mock-immunized rats to synthetic angiotensin II and norepine-
phrine
Baseline blood
pressure, mm Hga
Blood pressure rise, mm Hg
Angiotensin Norepinephrine
5x109g 5x109g
Mock-immunized
76 9 11
60 17 8
59 20 6
67 7 8
55 11 10
Mean±5EM 63±4 12.8±2.5 8.6±1.0
Angiotensin-immunized
52 4 9
50 2 8
50 2 7
65 4 11
72 6 12
62 7 8
68 6 12
65 5 11
66 4 8
58 5 11
75 4 ii
Mean±sEM 62±3 4.4±O.Sb 9.8±0.6
a After pentolinium tartrate, 2 mg administered s.c.
b Statistically different from mock-immunized, P< 0.001.
(Schwartz Bioresearch). A dilution of 1/24,000 of pre-
paration W3 was necessary to give the same binding.
Dilutions of 1/32,000 and 1/6,000 of PS1O and W3, re-
spectively, bound 50% of '251-Asp1-11e5-angiotensin I
(Schwartz Bioresearch). Thus, PS1O antibody had
essentially the same binding capacity for angiotensin II
as that obtained in the prior study of protection against
acute renal failure by passive immunization [13]. The
W3 preparation was less potent.
After isolation, 1 mg of freeze-dried antibody PS1O
dissolved in 1 ml of 0.9% NaCl and diluted 1/2,800
bound 50% of 10_li g of 1251-angiotensin II. Compar-
able binding with the W3 antibody preparation re-
quired a dilution of 1/1,200.
The blood pressure response of rats injected with
rabbit antiangiotensin globulin prior to challenge with
10_8 to 3 x l08 g of norepinephrine and angiotensin
is shown in Table 2. Both antibody preparations used,
PSIO and W3, caused a significant blunting of blood
pressure response with the three doses of angiotensin
used (P <0.001). Norepinephrine sensitivity was not
consistently changed.
Effect of passive immunization on glycerol-induced
renal failure. The change in BUN concentration, body
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wt, hematocrit value and '4C-inulin clearance 24 hr
after rats were challenged with myohemoglobinuria is
shown in Table 3. Essentially the same degree of azo-
temia was observed in rats given the two antibody pre-
parations as in those which received 0.6 ml of normal
rat serum in divided dosage and others given no injec-
tion prior to production of myohemoglobinuria. Inulin
clearances ranged from 0.003 ml to 0.173 ml/min/100 g
of body wt, all groups having a glomerular filtration
rate which was greatly lower than the normal control
value of 0.93 0.24 mI/min/l00 g of body wt (P<
0.0001, Table 4). In short, the animals were not pro-
tected from acute renal failure despite the injection of
9 to 13 times the amount of antibody which greatly re-
duced the blood pressure response to pharmacologic
doses of angiotensin.
Acute renal failure in actively immunized rats. The
change in BUN concentration, body wt and hemato-
crit value of rats actively immunized against synthetic
angiotensin is shown in Table 4. These rats were not
dehydrated prior to the injection of glycerol so as to
minimize the stimulus for acute renal failure and in-
crease the opportunity for circulating antiangiotensin
antibody to vitiate the development of acute renal
failure. The degree of azotemia observed in nondehy-
drated animals was significantly less than that in the
animals deprived of water for 14 hr before glycerol in-
jection (P <0.001). The rise in BUN concentration ob-
Table 2. Blood pressure response of passively immunized ratsa challenged with angiotensin and norepinephrine
Pressor Blood pressure rise, mm Hg
Control
(N=4)
Antibody injected
PSIO, 10 mg
(N=4)
W3, 20mg(N=l) W3, 35 mg(N=l)
Angiotensin, 108g
Norepinephrine, l08g
29±5(sEM)
9±2
8±2'
9±2
13
13
4
12
Angiotensin, 2x 10_ag
Norepinephrine, 2x 10_a g
40±8
26±2
17±3'
19±5
29
25
12
30
Angiotensin, 3 x 10 g
Norepinephrine, 3 x 10 g
52 5
34±5
27 3"
25±5
29
30
18
31
a Rats anesthetized with pentobarbital and given 2 mg of pentolinium s.c.
"Statistically different from control, P <0.001.
Table 3. The effect of passive immunization with rabbit antiangiotensin antibody on glycerol-induced hemoglobinuric acute
renal failure
Control Antibody
No Rx
(N=6)
Normal serum,
0.6 ml
(N=7)
PS1O, 110 mg/rat
(N=7)
PS1O, 135 mg/rat
(N=4)
W3, 178 mg/rat
(N=2)
Body wt, g
Baseline
Control dehydrated
24hrafterglycerol
234±9(sE)
218±8
224±10
230±7
235±9
235±11
226±5
212±5
207±6
227±5
220±9
222±8
210±22
192±28
198±26
Hematocrit, vol %
Baseline
Control dehydrated
24 hr after glycerol
46±1.5
50±0
35±2.4
46±0.9
45± 1.5
35±0.8
45±1.7
50± 1.2
34±2.8
45±1.5
46±2.2
37± 1.9
46±0.0
49±0.5
43±2.0
BUN, mg/100 ml
Baseline
Control dehydrated
24hrafterglycerol
19±0.424 2
211±10
20±2
18 1
151±67
20±2
23 1
159±27
18±3
22 3
181±12
16±324 2
191±12
GFR, ml/min/100 g of body wt
24 hr after glycerol 0.003±0.001 0.078±0.040 0.173±0.083 0.027±0.023 0.023±0.021
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Table 4. The effect of active angiotensin immunization and mock immunization on glycerol-induced acute
renal failure
Unimmunized
(N= 8)
Mock-immunized
(N= 9)
Angiotensin-immunized
(N= 16)
Body wt, g
Control
24hrafterglycerol
48 hr after glycerol
197±4(sEM)
191±4
187 3
258±5
249±5
245 3
267±6
262+7
260 7
BUN, mg/100 ml
Control
24 hr after glycerol
48 hr after glycerol
21±1
88±18
94±27
21±1
61±3
131
19±1
74±11
145±27
GFR, ml/min/JOO g of body wt
Control
24 hr after glycerol
0.93±0.24
0.023 0.0 17
(N= 5)
— —
0.030 0.018
(N= 4)
served in immunized rats 24 hr after glycerol injection
(74 ii [sEMI mg/100 ml) was not different from the
88 18 and 61 3 mg/lOG ml values obtained with
nonimmunized and mock-immunized series of rats
(P>0.1).
Discussion
Renal micropuncture studies have shown that gly-
cerol-induced, myohemoglobinuric renal failure in the
rat reflects a primary failure of glomerular filtration
which cannot be attributed to tubular obstruction or
passive back-flow of filtrate [17—20]. Renal blood flow
is significantly reduced in this model [21, 22] as in
other forms of acute renal failure [23—27], leading to
the hypothesis that changes in renovascular resistance
lower effective filtration pressure to the point that nor-
mal filtration is not possible. The mediator of such a
vascular aberration is unknown, but there is circum-
stantial evidence which tends to implicate the renin-
angiotensin axis [2—il]. Direct support for the angio-
tensin hypothesis was obtained recently by Powell-
Jackson et a!, who found that passively transferred
rabbit antiangiotensin antibody with a titer identical
to that used in the present study prevented rats from
developing glycerol-induced myohemoglobinuric acute
renal failure [13]. If, indeed, immune serum can pro-
tect rats from developing azotemia while control serum
does not, the postulate that the renin-angiotensin
axis plays an essential role in the pathogenesis of at
least this model of acute renal failure is indisputable.
Unfortunately, glycerol-induced renal failure is
greatly influenced by an animal's state of hydration at
the time of challenge. Allowed free access to water, 23
of 65 rats in a prior study failed to develop azotemia,
17 developed a mean BUN concentration of only
48 mg/100 ml, and 25 animals handled identically de-
veloped a BUN concentration of 151 mg/lOO ml 48 hr
after i.m. glycerol injection [28]. Why certain well-
hydrated rats develop renal failure while others, often
in the same groups, do not is entirely unclear [28].
Severe renal failure results universally if the animals
are dehydrated for 24 hr before being put at risk of
this form of renal failure [28], but the BUN rise can be
almost halved by expanding plasma volume with
1.4 ml/l00 g of body wt of normal rat plasma before
glycerol is injected [18]. While rats in the study of
Powell-Jackson et al were dehydrated before study and
had 1 ml of blood removed for baseline studies, they
were given 4.5 ml of immune serum i.v. in close proxi-
mity to the time that glycerol was injected. Such infu-
sions, equivalent to approximately 40% of normal rat
plasma volume [19], could have influenced the de-
velopment of acute renal failure in any given subgroup
of rats in a completely random fashion. Additionally,
in our hands (unpublished data), s.c. injected
glycerol is highly inconsistent in its capacity to
produce renal insufficiency in even dehydrated rats.
This is manifest also in the study of Powell-Jackson
et al [13]. The BUN concentration of their untreated
control animals injected s.c. with glycerol rose to only
57 mg/lOO ml in 48 hr, and their counterparts injected
with serum from unimmunized rabbits rose to only
46 mg/lOO ml. Comparable animals injected i.m. are
expected to achieve a BUN concentration greater than
200 mg/100 ml [17—20, 28]. Although statistically sig-
nificant differences in BUN concentration were ob-
tained in passively immunized rats in the earlier study,
the variability associated with s.c. administered gly-
cerol and plasma volume depletion prompted this re-
evaluation using a more consistent model of acute
renal failure.
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In the present study, rats were subjected to dehydra-
tion just sufficient to produce a consistent and moder-
ate degree of azotemia after glycerol injections, and
the volume of antibody infused was small. The amount
of gammaglobulin injected, although some 9 to 13
times more than needed to greatly blunt the hyper-
tensive effect of large amounts of angiotensin and
slightly more than that infused in whole serum by
Powell-Jackson et al [13], would not significantly affect
plasma oncotic pressure or plasma volume. Under
these experimental conditions, all groups of animals
developed comparable degrees of azotemia when
challenged with glycerol. Whole kidney inulin clear-
ance values of the seven rats given 110 mg of PS1O
antibody were statistically higher than those obtained
in animals that received no infusion at the time that
glycerol was injected. The difference was of little bio-
logic significance, however, and the four rats given
135 mg of the same preparation fared no better than
the unimmunized rats. In short, antiangiotensin anti-
body with a seemingly identical binding constant to
that which had appeared to protect rats from s.c. ad-
ministered glycerol before [13] was ineffectual when
injected in isolated form into rats subjected to a more
predictable lesion.
Active immunization against synthetic angiotensin II
also failed to significantly alter the degree of renal in-
sufficiency produced by glycerol injection. The rats in
this portion of the protocol were not dehydrated prior
to study so as to reduce the severity of renal injury and
maximize the opportunity to detect any degree of pro-
tection. Had protection been evident, it would then
have been necessary to rule out the variability in results
implicit to a study on nondehydrated animals. Despite
the fact that actively immunized animals were resistant
to the hypertensive effect of synthetic angiotensin II,
they experienced the same degree of azotemia as their
mock-immunized counterparts handled identically.
These experiments indicate that neither exogenously
nor endogenously produced circulating antiangiotensin
antibody of the potency obtained in this study was
capable of protecting rats from glycerol-induced myo-
hemoglobinuric renal failure.
Although the rats in both portions of this study
showed a markedly blunted pressor response to exo-
genous angiotensin, some sensitivity to angiotensin re-
mained. It is, then, possible that more effective im-
munization might have been at least partly protective.
Question could also be raised regarding the ability of
rat or rabbit antibody produced with synthetic angio-
tensin to neutralize native rat angiotensin with an as-
partyl rather than asparagine amide moiety and iso-
leucine rather than valine in position five. It has been
shown previously, however, that antibody to synthetic
angiotensin II formed in rats and rabbits is indeed cap-
able of neutralizing native rat angiotensin either in
vivo or in vitro [13, 15]. Additionally, there is some
evidence that the renin-angiotensin system might exert
its effect on the renal vasculature directly at the afferent
arteriole, independent of circulating angiotensin activ-
ity, and possibly at a site inaccessible to circulating
antibodies [8, 12]. In view of these reservations, the
present study cannot be construed as palpable evidence
that angiotensin plays no role in the pathogenesis of
acute renal failure, nor does it absolutely disprove that
protection observed in the prior study [13], where the
stimulus for renal failure was rather less severe, might
have related to immunization. It does, however, fail to
confirm that study which strongly suggested that cir-
culating angiotensin plays a direct and important role
in the pathogenesis of myohemoglobinuric acute renal
failure. A direct pathogenetic role of the renin system
at the glomerular vascular pole remains to be estab-
lished.
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